BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M, Izumi H, Nakamura T, Matsuo K, Yamada Y, Kohno K. Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer 2001;93:869-74. [PMID: 11519050 DOI: 10.1002/ijc.1418] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Wang BY, Zhang J, Wang JL, Sun S, Wang ZH, Wang LP, Zhang QL, Lv FF, Cao EY, Shao ZM, Fais S, Hu XC. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res 2015;34:85. [PMID: 26297142 DOI: 10.1186/s13046-015-0194-x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 12.0] [Reference Citation Analysis]
2 Ishiguchi H, Izumi H, Torigoe T, Yoshida Y, Kubota H, Tsuji S, Kohno K. ZNF143 activates gene expression in response to DNA damage and binds to cisplatin-modified DNA. Int J Cancer 2004;111:900-9. [DOI: 10.1002/ijc.20358] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
3 Dai Y, Tang Y, Xu X, Luo Z, Zhang Y, Li Z, Lin Z, Zhao S, Zeng M, Sun B, Cheng L, Zhu J, Xiong Z, Long H, Zhu Y, Yu K. Evaluation of the mechanisms and effects of Mg-Ag-Y alloy on the tumor growth and metastasis of the MG63 osteosarcoma cell line. J Biomed Mater Res B Appl Biomater 2019;107:2537-48. [PMID: 30779430 DOI: 10.1002/jbm.b.34344] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
4 Kulshrestha A, Katara GK, Ginter J, Pamarthy S, Ibrahim SA, Jaiswal MK, Sandulescu C, Periakaruppan R, Dolan J, Gilman-Sachs A, Beaman KD. Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells. Mol Oncol 2016;10:789-805. [PMID: 26899534 DOI: 10.1016/j.molonc.2016.01.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
5 García-garcía A, Pérez-sayáns M, Rodríguez M, Antúnez-lópez J, Barros-angueira F, Somoza-martín M, Gándara-rey J, Aguirre-urízar J. Immunohistochemical localization of C1 subunit of V-ATPase (ATPase C1) in oral squamous cell cancer and normal oral mucosa. Biotechnic & Histochemistry 2012;87:133-9. [DOI: 10.3109/10520295.2011.574647] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
6 Sancho-martínez SM, Prieto-garcía L, Prieto M, López-novoa JM, López-hernández FJ. Subcellular targets of cisplatin cytotoxicity: An integrated view. Pharmacology & Therapeutics 2012;136:35-55. [DOI: 10.1016/j.pharmthera.2012.07.003] [Cited by in Crossref: 108] [Cited by in F6Publishing: 104] [Article Influence: 10.8] [Reference Citation Analysis]
7 Harguindey S, Alfarouk K, Orozco JP, Hardonniere K, Stanciu D, Fais S, Devesa J. A New and Integral Approach to the Etiopathogenesis and Treatment of Breast Cancer Based upon Its Hydrogen Ion Dynamics. Int J Mol Sci 2020;21:E1110. [PMID: 32046158 DOI: 10.3390/ijms21031110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
8 Law ZJ, Khoo XH, Lim PT, Goh BH, Ming LC, Lee WL, Goh HP. Extracellular Vesicle-Mediated Chemoresistance in Oral Squamous Cell Carcinoma. Front Mol Biosci 2021;8:629888. [PMID: 33768115 DOI: 10.3389/fmolb.2021.629888] [Reference Citation Analysis]
9 Sistigu A, Di Modugno F, Manic G, Nisticò P. Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. Cytokine Growth Factor Rev 2017;36:67-77. [PMID: 28595838 DOI: 10.1016/j.cytogfr.2017.05.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
10 Gatti L, Cassinelli G, Zaffaroni N, Lanzi C, Perego P. New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants. Drug Resist Updat 2015;20:1-11. [PMID: 26003720 DOI: 10.1016/j.drup.2015.04.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
11 Stawicki TM, Owens KN, Linbo T, Reinhart KE, Rubel EW, Raible DW. The zebrafish merovingian mutant reveals a role for pH regulation in hair cell toxicity and function. Dis Model Mech 2014;7:847-56. [PMID: 24973752 DOI: 10.1242/dmm.016576] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
12 Palakurthi S, Yellepeddi VK, Vangara KK. Recent trends in cancer drug resistance reversal strategies using nanoparticles. Expert Opin Drug Deliv 2012;9:287-301. [PMID: 22339554 DOI: 10.1517/17425247.2012.665365] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
13 Harguindey S, Orive G, Luis Pedraz J, Paradiso A, Reshkin SJ. The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin--one single nature. Biochim Biophys Acta 2005;1756:1-24. [PMID: 16099110 DOI: 10.1016/j.bbcan.2005.06.004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 88] [Article Influence: 2.4] [Reference Citation Analysis]
14 Stransky L, Cotter K, Forgac M. The Function of V-ATPases in Cancer. Physiol Rev 2016;96:1071-91. [PMID: 27335445 DOI: 10.1152/physrev.00035.2015] [Cited by in Crossref: 123] [Cited by in F6Publishing: 106] [Article Influence: 24.6] [Reference Citation Analysis]
15 Dos Santos SC, Teixeira MC, Cabrito TR, Sá-Correia I. Yeast toxicogenomics: genome-wide responses to chemical stresses with impact in environmental health, pharmacology, and biotechnology. Front Genet 2012;3:63. [PMID: 22529852 DOI: 10.3389/fgene.2012.00063] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
16 Wakasugi T, Izumi H, Uchiumi T, Suzuki H, Arao T, Nishio K, Kohno K. ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes. Oncogene 2007;26:5194-203. [PMID: 17297437 DOI: 10.1038/sj.onc.1210326] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
17 Shirmanova MV, Druzhkova IN, Lukina MM, Dudenkova VV, Ignatova NI, Snopova LB, Shcheslavskiy VI, Belousov VV, Zagaynova EV. Chemotherapy with cisplatin: insights into intracellular pH and metabolic landscape of cancer cells in vitro and in vivo. Sci Rep 2017;7:8911. [PMID: 28827680 DOI: 10.1038/s41598-017-09426-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 8.4] [Reference Citation Analysis]
18 Chueca E, Apostolova N, Esplugues JV, García-González MA, Lanas Á, Piazuelo E. Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells. Front Pharmacol 2016;7:452. [PMID: 27932981 DOI: 10.3389/fphar.2016.00452] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
19 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
20 Diniz IMA, Souto GR, Freitas IDP, de Arruda JAA, da Silva JM, Silva TA, Mesquita RA. Photobiomodulation Enhances Cisplatin Cytotoxicity in a Culture Model with Oral Cell Lineages. Photochem Photobiol 2020;96:182-90. [PMID: 31424557 DOI: 10.1111/php.13152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, Rey JM, García-García A. V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev 2009;35:707-13. [PMID: 19758758 DOI: 10.1016/j.ctrv.2009.08.003] [Cited by in Crossref: 129] [Cited by in F6Publishing: 117] [Article Influence: 9.9] [Reference Citation Analysis]
22 Oh-hashi K, Kanamori Y, Hirata Y, Kiuchi K. Characterization of V-ATPase inhibitor-induced secretion of cysteine-rich with EGF-like domains 2. Cell Biol Toxicol 2014;30:127-36. [PMID: 24687431 DOI: 10.1007/s10565-014-9274-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
23 Loh D, Reiter RJ. Melatonin: Regulation of Biomolecular Condensates in Neurodegenerative Disorders. Antioxidants (Basel) 2021;10:1483. [PMID: 34573116 DOI: 10.3390/antiox10091483] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Patel TH, Norman L, Chang S, Abedi S, Liu C, Chwa M, Atilano SR, Thaker K, Lu S, Jazwinski SM, Miceli MV, Udar N, Bota D, Kenney MC. European mtDNA Variants Are Associated With Differential Responses to Cisplatin, an Anticancer Drug: Implications for Drug Resistance and Side Effects. Front Oncol 2019;9:640. [PMID: 31380278 DOI: 10.3389/fonc.2019.00640] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
25 Harguindey S, Stanciu D, Devesa J, Alfarouk K, Cardone RA, Polo Orozco JD, Devesa P, Rauch C, Orive G, Anitua E, Roger S, Reshkin SJ. Cellular acidification as a new approach to cancer treatment and to the understanding and therapeutics of neurodegenerative diseases. Semin Cancer Biol 2017;43:157-79. [PMID: 28193528 DOI: 10.1016/j.semcancer.2017.02.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
26 Chi SL, Pizzo SV. Cell surface F 1 F o ATP synthase: A new paradigm? Annals of Medicine 2009;38:429-38. [DOI: 10.1080/07853890600928698] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 6.5] [Reference Citation Analysis]
27 Fais S. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med. 2010;267:515-525. [PMID: 20433578 DOI: 10.1111/j.1365-2796.2010.02225.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 6.0] [Reference Citation Analysis]
28 You H, Jin J, Shu H, Yu B, De Milito A, Lozupone F, Deng Y, Tang N, Yao G, Fais S. Small interfering RNA targeting the subunit ATP6L of proton pump V-ATPase overcomes chemoresistance of breast cancer cells. Cancer Lett. 2009;280:110-119. [PMID: 19299075 DOI: 10.1016/j.canlet.2009.02.023] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
29 Hinton A, Bond S, Forgac M. V-ATPase functions in normal and disease processes. Pflugers Arch - Eur J Physiol 2009;457:589-98. [DOI: 10.1007/s00424-007-0382-4] [Cited by in Crossref: 139] [Cited by in F6Publishing: 136] [Article Influence: 9.3] [Reference Citation Analysis]
30 Spugnini EP, Baldi A, Buglioni S, Carocci F, de Bazzichini GM, Betti G, Pantaleo I, Menicagli F, Citro G, Fais S. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2011;9:221. [PMID: 22204495 DOI: 10.1186/1479-5876-9-221] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
31 Izumi H, Wakasugi T, Shimajiri S, Tanimoto A, Sasaguri Y, Kashiwagi E, Yasuniwa Y, Akiyama M, Han B, Wu Y, Uchiumi T, Arao T, Nishio K, Yamazaki R, Kohno K. Role of ZNF143 in tumor growth through transcriptional regulation of DNA replication and cell-cycle-associated genes. Cancer Sci 2010;101:2538-45. [PMID: 20860770 DOI: 10.1111/j.1349-7006.2010.01725.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
32 Torigoe T, Izumi H, Ise T, Murakami T, Uramoto H, Ishiguchi H, Yoshida Y, Tanabe M, Nomoto M, Kohno K. Vacuolar H(+)-ATPase: functional mechanisms and potential as a target for cancer chemotherapy. Anticancer Drugs 2002;13:237-43. [PMID: 11984067 DOI: 10.1097/00001813-200203000-00005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
33 Miyamoto N, Izumi H, Noguchi T, Nakajima Y, Ohmiya Y, Shiota M, Kidani A, Tawara A, Kohno K. Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance. J Biol Chem 2008;283:18218-26. [PMID: 18458078 DOI: 10.1074/jbc.M802332200] [Cited by in Crossref: 56] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
34 Mcsheehy P, Troy H, Kelland L, Judson I, Leach M, Griffiths J. Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics. European Journal of Cancer 2003;39:532-40. [DOI: 10.1016/s0959-8049(02)00671-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
35 Izumi H, Torigoe T, Ishiguchi H, Uramoto H, Yoshida Y, Tanabe M, Ise T, Murakami T, Yoshida T, Nomoto M, Kohno K. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treatment Reviews 2003;29:541-9. [DOI: 10.1016/s0305-7372(03)00106-3] [Cited by in Crossref: 445] [Cited by in F6Publishing: 107] [Article Influence: 23.4] [Reference Citation Analysis]
36 Igarashi T, Izumi H, Uchiumi T, Nishio K, Arao T, Tanabe M, Uramoto H, Sugio K, Yasumoto K, Sasaguri Y. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene. 2007;26:4749-4760. [PMID: 17297441 DOI: 10.1038/sj.onc.1210289] [Cited by in Crossref: 99] [Cited by in F6Publishing: 85] [Article Influence: 6.6] [Reference Citation Analysis]
37 Chiche J, Brahimi-Horn MC, Pouysségur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med 2010;14:771-94. [PMID: 20015196 DOI: 10.1111/j.1582-4934.2009.00994.x] [Cited by in Crossref: 370] [Cited by in F6Publishing: 351] [Article Influence: 28.5] [Reference Citation Analysis]
38 Hamm R, Sugimoto Y, Steinmetz H, Efferth T. Resistance mechanisms of cancer cells to the novel vacuolar H+-ATPase inhibitor archazolid B. Invest New Drugs 2014;32:893-903. [DOI: 10.1007/s10637-014-0134-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
39 Kitazawa S, Nishizawa S, Nakagawa H, Funata M, Nishimura K, Soga T, Hara T. Cancer with low cathepsin D levels is susceptible to vacuolar (H+ )-ATPase inhibition. Cancer Sci 2017;108:1185-93. [PMID: 28317223 DOI: 10.1111/cas.13240] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
40 Hraběta J, Belhajová M, Šubrtová H, Merlos Rodrigo MA, Heger Z, Eckschlager T. Drug Sequestration in Lysosomes as One of the Mechanisms of Chemoresistance of Cancer Cells and the Possibilities of Its Inhibition. Int J Mol Sci 2020;21:E4392. [PMID: 32575682 DOI: 10.3390/ijms21124392] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
41 Tanaka F, Whitworth CA, Rybak LP. Influence of pH on the ototoxicity of cisplatin: a round window application study. Hear Res 2003;177:21-31. [PMID: 12618314 DOI: 10.1016/s0378-5955(02)00771-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
42 Whitton B, Okamoto H, Packham G, Crabb SJ. Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer. Cancer Med 2018;7:3800-11. [PMID: 29926527 DOI: 10.1002/cam4.1594] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 12.0] [Reference Citation Analysis]
43 Raudenska M, Balvan J, Fojtu M, Gumulec J, Masarik M. Unexpected therapeutic effects of cisplatin. Metallomics 2019;11:1182-99. [PMID: 31098602 DOI: 10.1039/c9mt00049f] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
44 Lu ZN, Tian B, Guo XL. Repositioning of proton pump inhibitors in cancer therapy. Cancer Chemother Pharmacol 2017;80:925-37. [PMID: 28861639 DOI: 10.1007/s00280-017-3426-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
45 Guo X, Tang Y, Zhu W. Distinct esophageal adenocarcinoma molecular subtype has subtype-specific gene expression and mutation patterns. BMC Genomics 2018;19:769. [PMID: 30355311 DOI: 10.1186/s12864-018-5165-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
46 Berthenet K, Castillo Ferrer C, Fanfone D, Popgeorgiev N, Neves D, Bertolino P, Gibert B, Hernandez-Vargas H, Ichim G. Failed Apoptosis Enhances Melanoma Cancer Cell Aggressiveness. Cell Rep 2020;31:107731. [PMID: 32521256 DOI: 10.1016/j.celrep.2020.107731] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
47 Fais S, Venturi G, Gatenby B. Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Metastasis Rev 2014;33:1095-108. [PMID: 25376898 DOI: 10.1007/s10555-014-9531-3] [Cited by in Crossref: 100] [Cited by in F6Publishing: 98] [Article Influence: 14.3] [Reference Citation Analysis]
48 Procházka P, Libra A, Zemanová Z, Hřebačková J, Poljaková J, Hraběta J, Bunček M, Stiborová M, Eckschlager T. Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells. Cancer Science 2012;103:334-41. [DOI: 10.1111/j.1349-7006.2011.02137.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
49 Huang Y, Sadée W. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Letters 2006;239:168-82. [DOI: 10.1016/j.canlet.2005.07.032] [Cited by in Crossref: 138] [Cited by in F6Publishing: 132] [Article Influence: 8.6] [Reference Citation Analysis]
50 Harguindey S, Alfarouk K, Polo Orozco J, Fais S, Devesa J. Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New H+-Centered Anticancer Paradigm of the Late Post-Warburg Era. Int J Mol Sci 2020;21:E7475. [PMID: 33050492 DOI: 10.3390/ijms21207475] [Reference Citation Analysis]
51 Laurell G, Videhult Pierre P. Hearing Loss After Cisplatin: Oxidative Stress Pathways and Potential for Protection. In: Miller J, Le Prell CG, Rybak L, editors. Free Radicals in ENT Pathology. Cham: Springer International Publishing; 2015. pp. 217-41. [DOI: 10.1007/978-3-319-13473-4_11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
52 Stevens SK, Strehle AP, Miller RL, Gammons SH, Hoffman KJ, McCarty JT, Miller ME, Stultz LK, Hanson PK. The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae. Mol Pharmacol 2013;83:225-34. [PMID: 23090979 DOI: 10.1124/mol.112.079657] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
53 Zhang JL, Liu M, Yang Q, Lin SY, Shan HB, Wang HY, Xu GL. Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer. World J Gastroenterol 2017; 23(14): 2575-2584 [PMID: 28465642 DOI: 10.3748/wjg.v23.i14.2575] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
54 Wang J, Nishiyama A, Matsuyama M, Wang Z, Yuan Y. The (pro)renin receptor: a novel biomarker and potential therapeutic target for various cancers. Cell Commun Signal 2020;18:39. [PMID: 32143717 DOI: 10.1186/s12964-020-0531-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
55 Izumi H, Ohta R, Nagatani G, Ise T, Nakayama Y, Nomoto M, Kohno K. p300/CBP-associated factor (P/CAF) interacts with nuclear respiratory factor-1 to regulate the UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyltransferase-3 gene. Biochem J 2003;373:713-22. [PMID: 12720548 DOI: 10.1042/BJ20021902] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
56 Abumanhal-Masarweh H, Koren L, Zinger A, Yaari Z, Krinsky N, Kaneti G, Dahan N, Lupu-Haber Y, Suss-Toby E, Weiss-Messer E, Schlesinger-Laufer M, Shainsky-Roitman J, Schroeder A. Sodium bicarbonate nanoparticles modulate the tumor pH and enhance the cellular uptake of doxorubicin. J Control Release 2019;296:1-13. [PMID: 30615983 DOI: 10.1016/j.jconrel.2019.01.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 8.3] [Reference Citation Analysis]
57 Federici C, Petrucci F, Caimi S, Cesolini A, Logozzi M, Borghi M, D'Ilio S, Lugini L, Violante N, Azzarito T, Majorani C, Brambilla D, Fais S. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One 2014;9:e88193. [PMID: 24516610 DOI: 10.1371/journal.pone.0088193] [Cited by in Crossref: 198] [Cited by in F6Publishing: 195] [Article Influence: 24.8] [Reference Citation Analysis]
58 Valiahdi SM, Egger AE, Miklos W, Jungwirth U, Meelich K, Nock P, Berger W, Hartinger CG, Galanski M, Jakupec MA, Keppler BK. Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes. J Biol Inorg Chem 2013;18:249-60. [PMID: 23354303 DOI: 10.1007/s00775-012-0970-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
59 Kiyoshima T, Yoshida H, Wada H, Nagata K, Fujiwara H, Kihara M, Hasegawa K, Someya H, Sakai H. Chemoresistance to concanamycin A1 in human oral squamous cell carcinoma is attenuated by an HDAC inhibitor partly via suppression of Bcl-2 expression. PLoS One 2013;8:e80998. [PMID: 24278362 DOI: 10.1371/journal.pone.0080998] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
60 Harguindey S, Arranz JL, Polo Orozco JD, Rauch C, Fais S, Cardone RA, Reshkin SJ. Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs--an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research. J Transl Med 2013;11:282. [PMID: 24195657 DOI: 10.1186/1479-5876-11-282] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 10.7] [Reference Citation Analysis]
61 Parissenti AM, Hembruff SL, Villeneuve DJ, Veitch Z, Guo B, Eng J. Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells. Anticancer Drugs 2007;18:499-523. [PMID: 17414620 DOI: 10.1097/CAD.0b013e3280262427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
62 Hsu JL, Liu FL, Hsu LC, Chang HS, Leu WJ, Yu CC, Chang WL, Chen IS, Kung FL, Guh JH. Epi-reevesioside F inhibits Na+/K+-ATPase, causing cytosolic acidification, Bak activation and apoptosis in glioblastoma. Oncotarget 2015;6:24032-46. [PMID: 26125228 DOI: 10.18632/oncotarget.4429] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
63 Xue X, Hall MD, Zhang Q, Wang PC, Gottesman MM, Liang XJ. Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking. ACS Nano 2013;7:10452-64. [PMID: 24219825 DOI: 10.1021/nn405004f] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 6.7] [Reference Citation Analysis]
64 Spugnini EP, Buglioni S, Carocci F, Francesco M, Vincenzi B, Fanciulli M, Fais S. High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2014;12:225. [PMID: 25143012 DOI: 10.1186/s12967-014-0225-y] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
65 Chauhan SS, Liang XJ, Su AW, Pai-Panandiker A, Shen DW, Hanover JA, Gottesman MM. Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br J Cancer 2003;88:1327-34. [PMID: 12698203 DOI: 10.1038/sj.bjc.6600861] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 3.8] [Reference Citation Analysis]
66 Hinton A, Sennoune SR, Bond S, Fang M, Reuveni M, Sahagian GG, Jay D, Martinez-Zaguilan R, Forgac M. Function of a subunit isoforms of the V-ATPase in pH homeostasis and in vitro invasion of MDA-MB231 human breast cancer cells. J Biol Chem 2009;284:16400-8. [PMID: 19366680 DOI: 10.1074/jbc.M901201200] [Cited by in Crossref: 140] [Cited by in F6Publishing: 82] [Article Influence: 10.8] [Reference Citation Analysis]
67 Lee EL, Shimizu T, Ise T, Numata T, Kohno K, Okada Y. Impaired activity of volume-sensitive Cl− channel is involved in cisplatin resistance of cancer cells. J Cell Physiol 2007;211:513-21. [DOI: 10.1002/jcp.20961] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 3.9] [Reference Citation Analysis]
68 Marcucci F, Bellone M, Caserta CA, Corti A. Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads. Int J Cancer 2014;135:1265-76. [PMID: 24174383 DOI: 10.1002/ijc.28572] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
69 Pamarthy S, Kulshrestha A, Katara GK, Beaman KD. The curious case of vacuolar ATPase: regulation of signaling pathways. Mol Cancer. 2018;17:41. [PMID: 29448933 DOI: 10.1186/s12943-018-0811-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 13.8] [Reference Citation Analysis]
70 Fogarty FM, O'keeffe J, Zhadanov A, Papkovsky D, Ayllon V, O'connor R. HRG-1 enhances cancer cell invasive potential and couples glucose metabolism to cytosolic/extracellular pH gradient regulation by the vacuolar-H+ ATPase. Oncogene 2014;33:4653-63. [DOI: 10.1038/onc.2013.403] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
71 Mcintyre A, Harris AL. The Role of pH Regulation in Cancer Progression. In: Cramer T, A. Schmitt C, editors. Metabolism in Cancer. Cham: Springer International Publishing; 2016. pp. 93-134. [DOI: 10.1007/978-3-319-42118-6_5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
72 Spugnini EP, Citro G, Fais S. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res. 2010;29:44. [PMID: 20459683 DOI: 10.1186/1756-9966-29-44] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 6.4] [Reference Citation Analysis]
73 Chung C, Mader CC, Schmitz JC, Atladottir J, Fitchev P, Cornwell ML, Koleske AJ, Crawford SE, Gorelick F. The vacuolar-ATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer. Lab Invest. 2011;91:732-743. [PMID: 21339745 DOI: 10.1038/labinvest.2011.8] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 6.8] [Reference Citation Analysis]
74 Izumi H, Ise T, Murakami T, Torigoe T, Ishiguchi H, Uramoto H, Yoshida Y, Yoshida T, Tanabe M, Kohno K. Structural and functional characterization of two human V-ATPase subunit gene promoters. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 2003;1628:97-104. [DOI: 10.1016/s0167-4781(03)00119-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
75 Kulshrestha A, Katara GK, Ibrahim SA, Riehl V, Sahoo M, Dolan J, Meinke KW, Pins MR, Beaman KD. Targeting V-ATPase Isoform Restores Cisplatin Activity in Resistant Ovarian Cancer: Inhibition of Autophagy, Endosome Function, and ERK/MEK Pathway. J Oncol 2019;2019:2343876. [PMID: 31057611 DOI: 10.1155/2019/2343876] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
76 Balza E, Carlone S, Carta S, Piccioli P, Cossu V, Marini C, Sambuceti G, Rubartelli A, Castellani P. Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models. Cancer Med 2021. [PMID: 34796694 DOI: 10.1002/cam4.4371] [Reference Citation Analysis]
77 Zhang M, Saad C, Le L, Halfter K, Bauer B, Mansmann UR, Li J. Computational modeling of methionine cycle-based metabolism and DNA methylation and the implications for anti-cancer drug response prediction. Oncotarget 2018;9:22546-58. [PMID: 29875994 DOI: 10.18632/oncotarget.24547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
78 Pérez-sayáns M, Somoza-martín JM, Barros-angueira F, Diz PG, Rey JMG, García-garcía A. Multidrug resistance in oral squamous cell carcinoma: The role of vacuolar ATPases. Cancer Letters 2010;295:135-43. [DOI: 10.1016/j.canlet.2010.03.019] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
79 De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 2005;1:779-786. [PMID: 16556057 DOI: 10.2217/14796694.1.6.779] [Cited by in Crossref: 167] [Cited by in F6Publishing: 154] [Article Influence: 11.1] [Reference Citation Analysis]
80 Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Critical Reviews in Oncology/Hematology 2007;63:12-31. [DOI: 10.1016/j.critrevonc.2007.02.001] [Cited by in Crossref: 410] [Cited by in F6Publishing: 382] [Article Influence: 27.3] [Reference Citation Analysis]
81 Daniel C, Bell C, Burton C, Harguindey S, Reshkin SJ, Rauch C. The role of proton dynamics in the development and maintenance of multidrug resistance in cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2013;1832:606-17. [DOI: 10.1016/j.bbadis.2013.01.020] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 7.7] [Reference Citation Analysis]
82 Perut F, Avnet S, Fotia C, Baglìo SR, Salerno M, Hosogi S, Kusuzaki K, Baldini N. V-ATPase as an effective therapeutic target for sarcomas. Experimental Cell Research 2014;320:21-32. [DOI: 10.1016/j.yexcr.2013.10.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
83 Tanaka F, Whitworth CA, Rybak LP. Round window pH manipulation alters the ototoxicity of systemic cisplatin. Hear Res 2004;187:44-50. [PMID: 14698086 DOI: 10.1016/s0378-5955(03)00330-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
84 Torigoe T, Izumi H, Ishiguchi H, Uramoto H, Murakami T, Ise T, Yoshida Y, Tanabe M, Nomoto M, Itoh H. Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents. J Biol Chem. 2002;277:36534-36543. [PMID: 12133827 DOI: 10.1074/jbc.m202605200] [Cited by in Crossref: 60] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
85 Zorbas-seifried S, Hartinger CG, Meelich K, Galanski M, Keppler BK, Zorbas H. DNA Interactions of pH-Sensitive, Antitumor Bis(aminoalcohol)dichloroplatinum(II) Complexes ,. Biochemistry 2006;45:14817-25. [DOI: 10.1021/bi061063i] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
86 Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96:1702-1713. [PMID: 15547183 DOI: 10.1093/jnci/djh305] [Cited by in Crossref: 277] [Cited by in F6Publishing: 249] [Article Influence: 15.4] [Reference Citation Analysis]
87 Liao C, Hu B, Arno MJ, Panaretou B. Genomic screening in vivo reveals the role played by vacuolar H+ ATPase and cytosolic acidification in sensitivity to DNA-damaging agents such as cisplatin. Mol Pharmacol 2007;71:416-25. [PMID: 17093137 DOI: 10.1124/mol.106.030494] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
88 Yoshida T, Izumi H, Uchiumi T, Sasaguri Y, Tanimoto A, Matsumoto T, Naito S, Kohno K. Expression and cellular localization of dbpC/Contrin in germ cell tumor cell lines. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 2006;1759:80-8. [DOI: 10.1016/j.bbaexp.2006.02.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
89 Lozupone F, Borghi M, Marzoli F, Azzarito T, Matarrese P, Iessi E, Venturi G, Meschini S, Canitano A, Bona R, Cara A, Fais S. TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells. Oncogene 2015;34:5163-74. [PMID: 25659576 DOI: 10.1038/onc.2014.437] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
90 Almasi S, El Hiani Y. Exploring the Therapeutic Potential of Membrane Transport Proteins: Focus on Cancer and Chemoresistance. Cancers (Basel) 2020;12:E1624. [PMID: 32575381 DOI: 10.3390/cancers12061624] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
91 Kohno K, Wang KY, Takahashi M, Kurita T, Yoshida Y, Hirakawa M, Harada Y, Kuma A, Izumi H, Matsumoto S. Mitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer Chemotherapy. Int J Mol Sci 2015;16:19836-50. [PMID: 26307971 DOI: 10.3390/ijms160819836] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]